Get the Stockscreener App
20.23
0.30%
0.06
After Hours:
20.23
Zenas Biopharma Inc stock is traded at $20.23, with a volume of 556.16K.
It is up +0.30% in the last 24 hours and up +27.23% over the past month.
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.
See More
Previous Close:
$20.17
Open:
$20.14
24h Volume:
556.16K
Relative Volume:
2.81
Market Cap:
$851.89M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-1.37%
1M Performance:
+27.23%
6M Performance:
+146.41%
1Y Performance:
+0.00%
1-Day Range:
$19.80
$21.72
1-Week Range:
$19.68
$22.33
52-Week Range:
$5.83
$26.25
Zenas Biopharma Inc Stock (ZBIO) Company Profile
Name
Zenas Biopharma Inc
Sector
Industry
Phone
857-271-2954
Address
852 WINTER STREET, SUITE 250, WALTHAM
Compare ZBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZBIO
Zenas Biopharma Inc
|
20.23 | 833.36M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-20-25 | Initiated | Wedbush | Outperform |
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Dec-16-24 | Initiated | H.C. Wainwright | Buy |
| Nov-05-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-08-24 | Initiated | Citigroup | Buy |
| Oct-08-24 | Initiated | Guggenheim | Buy |
| Oct-08-24 | Initiated | Jefferies | Buy |
| Oct-08-24 | Initiated | Morgan Stanley | Overweight |
View All
Zenas Biopharma Inc Stock (ZBIO) Latest News
Can you recover from losses in Zenas BioPharma Inc.2025 Stock Rankings & Community Consensus Stock Picks - Newser
Can Zenas BioPharma Inc. hit a new high this monthMarket Growth Review & Free Fast Gain Swing Trade Alerts - Newser
Should you hold or exit Zenas BioPharma Inc. nowJuly 2025 Sector Moves & Short-Term High Return Ideas - Newser
Zenas BioPharma (NASDAQ:ZBIO) Trading Down 7.1%What's Next? - MarketBeat
Is Zenas BioPharma Inc. meeting your algorithmic filter criteria2025 Buyback Activity & Free Long-Term Investment Growth Plans - Newser
Candlestick signals on Zenas BioPharma Inc. stock todayJuly 2025 Retail & Free High Return Stock Watch Alerts - Newser
Real time pattern detection on Zenas BioPharma Inc. stock2025 Performance Recap & Detailed Earnings Play Strategies - Newser
How institutional ownership impacts Zenas BioPharma Inc. stockGap Up & Breakout Confirmation Trade Signals - Newser
Zenas BioPharma and Royalty Pharma enter into Obexelimab funding agreement for $300M - MSN
How moving averages guide Zenas BioPharma Inc. tradingMarket Risk Analysis & Pattern Based Trade Signal System - Newser
What MACD and RSI say about Zenas BioPharma Inc.Market Movement Recap & Low Risk Investment Opportunities - Newser
Sentiment analysis tools applied to Zenas BioPharma Inc.July 2025 Chart Watch & Weekly Watchlist for Hot Stocks - Newser
Real time breakdown of Zenas BioPharma Inc. stock performanceJuly 2025 Outlook & Growth Focused Entry Reports - Newser
Trend analysis for Zenas BioPharma Inc. this weekWeekly Trade Recap & Intraday High Probability Alerts - Newser
Nuveen LLC Invests $250,000 in Zenas BioPharma, Inc. $ZBIO - MarketBeat
Royalty Pharma plc (RPRX) Commits $300M to Zenas’ Obexelimab Program - Yahoo Finance
Zenas BioPharma (NASDAQ:ZBIO) Rating Increased to Hold at Wall Street Zen - MarketBeat
What does recent volatility data suggest for Zenas BioPharma Inc.Market Volume Report & Low Drawdown Momentum Trade Ideas - Newser
Applying Elliott Wave Theory to Zenas BioPharma Inc.Trade Entry Report & Smart Money Movement Tracker - Newser
Wedbush Has Bullish Outlook for Zenas BioPharma Q3 Earnings - MarketBeat
Can swing trading help recover from Zenas BioPharma Inc. lossesPortfolio Value Summary & Daily Entry Point Alerts - Newser
How to integrate Zenas BioPharma Inc. into portfolio analysis tools2025 AllTime Highs & Free Reliable Trade Execution Plans - Newser
Pattern recognition hints at Zenas BioPharma Inc. upside - Newser
Analyzing recovery setups for Zenas BioPharma Inc. investorsProduct Launch & Reliable Price Action Trade Plans - Newser
Top chart patterns to watch in Zenas BioPharma Inc.Weekly Risk Summary & Safe Entry Momentum Stock Tips - Newser
How to escape a deep drawdown in Zenas BioPharma Inc.2025 EndofYear Setup & Stock Portfolio Risk Control - Newser
What institutional flow reveals about Zenas BioPharma Inc.Quarterly Profit Review & Long-Term Capital Growth Strategies - Newser
Bronstein, Gewirtz & Grossman, LLC Encourages Zenas BioPharma, Inc. (ZBIO) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Measuring Zenas BioPharma Inc.’s beta against major indicesEarnings Miss & Daily Profit Focused Stock Screening - Newser
Tick level data insight on Zenas BioPharma Inc. volatilityJuly 2025 Big Picture & Weekly High Return Stock Forecasts - Newser
What machine learning models say about Zenas BioPharma Inc.Portfolio Growth Summary & Daily Growth Stock Tips - Newser
Zenas BioPharma Inc. Pullback Analyzed — Is It Time to ExitJuly 2025 Setups & Smart Allocation Stock Reports - beatles.ru
Heatmap analysis for Zenas BioPharma Inc. and competitors2025 Macro Impact & Verified Momentum Watchlists - Newser
Using fundamentals and technicals on Zenas BioPharma Inc.Weekly Stock Recap & Real-Time Volume Analysis - Newser
Can Zenas BioPharma Inc. reach all time highs this yearTrade Volume Summary & Community Verified Watchlist Alerts - beatles.ru
Zenas Biopharma Inc Stock (ZBIO) Financials Data
There is no financial data for Zenas Biopharma Inc (ZBIO). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):